Friday, July 10, 2026

pharma · Eczema · GERD (Heartburn, Regurgitation, and Dyspepsia) Frequency

Hong Kong Baptist

Hong Kong Baptist drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

CN HQ
NMPA registrant Type
Company details
Status
Public
HQ
CN
Programs
18
Drugs
14
Patents
0
Intelligence · Drug Pipeline

Hong Kong Baptist pipeline

Portfolio lens on 14 drugs and development assets — regulatory status, targets, and deep links to NovaPharmaNews drug profiles.

Hong Kong Baptist drug portfolio — 14 indexed compounds with therapeutic class and molecular targets from public FDA and regional approval metadata.

Drug portfolio

14 compounds
  1. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  2. US regulatory status: approved. Molecular target: Bacterial penicillin-binding protein.

    Target
    Bacterial penicillin-binding protein
    Mechanism
    Bacterial penicillin-binding protein inhibitor
  3. US regulatory status: approved. Molecular target: Bacterial 70S ribosome.

    Target
    Bacterial 70S ribosome
    Mechanism
    Matrix metalloproteinase-1 inhibitor
  4. exenatide

    Alimentary tract and metabolism (A10)

    Alimentary tract and metabolism (A10) compound in Hong Kong Baptist's portfolio. Molecular target: Glucagon-like peptide 1 receptor.

    Target
    Glucagon-like peptide 1 receptor
    Mechanism
    Glucagon-like peptide 1 receptor agonist
  5. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  6. Development asset linked to Hong Kong Baptist in public FDA and regional records. Molecular target: Insulin receptor.

    Target
    Insulin receptor
    Mechanism
    Insulin receptor agonist
  7. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  8. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  9. US regulatory status: approved. Molecular target: GABA-A receptor; anion channel.

    Target
    GABA-A receptor; anion channel
    Mechanism
    GABA-A receptor; anion channel agonist
  10. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  11. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  12. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  13. Development asset linked to Hong Kong Baptist in public FDA and regional records.

  14. Development asset linked to Hong Kong Baptist in public FDA and regional records.